

Les datas: pourquoi faire?

Notre expérience

Docteur Paul Stroumza

Directeur médical Diaverum France

Maladie rénale chronique: Actualité et
devenir de la prise en charge
21 juin 2016 – Paris



DIAVERUM

Comment délivrer la même qualité partout


20 countries

345 clinics

9,000 employees

>30000 patients in clinic

>4.5 million treatments p.a.



*No of clinics as of Jan 31, 2016

Conséquences financières de l'IRC



- En 2010, le nombre de patients en IRCT dans le monde était estimé à 3 millions
- Le coût de la prise en charge de ces patients avoisinait 1 trillion de US\$
- Fin 2014 , 45000 Patients sont dialysés en France (35000 greffés). Le coût moyen annuel est d'environ 80000€ par patient.
- Enorme poids des soins de santé pour la société!

Le challenge aujourd'hui



Réduire le coût des soins de dialyse, et simultanément améliorer la qualité des soins et assurer la sécurité des patients

Comment réussir?



- Fournir des soins de grande qualité médicale avec une faible variabilité à travers le monde
- Toujours prioriser la sécurité des patients
- Travailler en accord avec l'évidence scientifique
- Recueillir régulièrement des données auprès des cliniques pour mesurer la performance (scoring)



DIAVERUM

Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAVERUM

Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM

Standards of Care

Standards of Care in Hemodialysis 2013-2014

Rationale, explanations and elaborations

November 1, 2013



Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM

Collecter les données est important



- Assurer la sensibilisation sur la qualité et la sécurité du traitement
- Etre conforme aux réglementations et recommandations nationales et internationales
- Suivre les résultats et analyser les écarts améliore la qualité en soi
- Faire preuve d'excellence dans les soins auprès des intervenants différents (patients, famille, correspondants, tutelle et payeurs)
- Etre payé pour la performance un jour?



DIAVERUM

Clinical Performance Measures (CPM) en Hémodialyse 2016




- Kt/V (single pool) ≥ 1.4
- Albumine ≥ 35 g/l
- Hémoglobine ≥ 10.0 and ≤ 12.0 g/dl
- Ferritine ≥ 200 and ≤ 800 μ g/l
- Phosphore ≥ 2.5 and ≤ 5.5 mg/dl
- Calcium x Phosphore < 55 mg²/dl²
- PTH intacte ≥ 150 and ≤ 600 pg/ml
- Pression artérielle moyenne avant dialyse < 105 mmHg
- Prise de poids interdialytique $< 4\%$
- Durée hebdomadaire de traitement ≥ 720 minutes
- Prévalence des FAV

Calcul du CPM score

Quality Indicator	Quarter 1 (%)	Quarter 2 (%)	Quarter 3 (%)	Quarter 1 - 3
Kt/V ≥1.4	88.0	88.0	88.3	264.3
Albumin ≥35 g/L	92.5	93.9	94.5	280.9
Hemoglobin ≥10 and ≤12 g/dL	78.2	79.0	77.1	234.3
Ferritin ≥200 and ≤800 µg/L	79.7	80.6	74.0	234.3
Phosphorus ≥2.5 and ≤5.5 mg/dL	77.3	79.8	80.3	237.4
Ca x P <55 mg ² /dL ²	88.7	89.5	89.9	268.1
iPTH ≥150 and ≤600 pg/mL	68.6	79.0	69.7	217.3
Predialysis MAP <105 mmHg	90.6	89.8	87.3	267.7
IDBWG < 4% of dry weight	84.0	82.7	80.8	247.5
Weekly treatment time ≥720 min	79.9	81.6	84.5	246.0
AV fistula prevalence	76.4	75.6	77.9	229.9
CPM score	903.9	919.5	904.3	2727.7




Durée de traitement




DIAVERUM


Dose de dialyse



Prise de poids interdialytique




Augmentation progressive du CPM score




Risque de mortalité et d'hospitalization selon le CPM score

FOR EVERY 100 POINTS INCREASE IN CPM SCORE, ALL-CAUSE MORTALITY RISK DECREASED BY 33%, WITH A 95% CI OF 31% TO 35% ($P < 0.001$)



FOR EVERY 100 POINTS INCREASE IN CPM SCORE, THE RISK OF HOSPITALIZATIONS DECREASED BY 17%, WITH A 95% CI OF 15% TO 19% ($P < 0.001$)



Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM


Reporting des incidents et gestion des risques

- Nous avons **45315 incidents** rapportés en 2015
- Soit 1.70 (1.51 en 2014) incidents par patient et par an
- Cela fait **1** incident pour 100 séances d'hémodialyse environ



DIAVERUM

Top 10 incidents 2015



Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM


Audit clinique annuel

- 1. Uniforms
- 2. Use of PPE
- 3. Hand hygiene
- 4. Set up and priming
- 5. Patient assessment
- 6. Prescription
- 7. Medications and anticoagulation
- 8. AV access needling
- 9. CVC care
- 10. Connection process
- 11. Blood flow optimization
- 12. Documentation and monitoring
- 13. Rinse back
- 14. Post dialysis care
- 15. Sharps disposal
- 16. Waste disposal
- 17. Hygiene and maintenance of dialysis fluid pathway
- 18. External decontamination of dialysis monitor
- 19. Cleaning of dialysis station and area
- 20. Food provision during dialysis
- 21. HBV/HCV
- 22. Reuse
- 23. Emergency equipment/preparedness
- 24. Supplies and storage
- 25. Clinic environment
- 26. Water treatment
- 27. Quality and regulatory
- 28. Peritoneal dialysis



Audit de pratiques cliniques

Exemple:



Clinics with a pre or post integration audit, or a de-novo audit



Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM

Revues trimestrielles qualité

Quarter meetings

Réunion pluri-professionnelle par centre


- Bilan du précédent plan d'action
- Analyse des indicateurs du trimestre
- Nouveau plan d'action



DIAVERUM

Revues trimestrielles qualité

Quarter meetings

Diaverum France	Type de document Politique	Page 1 sur 2
Titre du document Revues Trimestrielles Qualité (QM)	N° du document 216	N° de version 04
Rédigé par S Schön, J Hegbrant, R Persson, D del Castillo, M Guerra; 2013-05-06	Date de mise en application 01/09/2013	
Validation du Directeur Médical DIAVERUM France : P Stroumza 	Validation du Directeur Général DIAVERUM France : H Gourgouillon 	
Application Tout Centre de Dialyse Diaverum		

Objet :

- Réaliser un suivi systématique, objectif et exhaustif des indicateurs permettant d'évaluer la qualité des soins de chaque centre de dialyse.
- Identifier les axes d'amélioration et définir les plans d'actions à mettre en place.
- S'assurer que les Revues Trimestrielles (Quarter Meeting : QM) sont réalisées selon le format standardisé.



DIAVERUM

Outils

Standards of care

Reportings et CPM score

Evènements indésirables

Audit clinique annuel

Revues trimestrielles

Recherche et publications



DIAPERUM

Publications

BMJ Open Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study

Suetonia C Palmer,¹ Marinella Ruospo,^{2,3} Katrina L Campbell,⁴
Vanessa Garcia Larsen,⁵ Valeria Saglimbene,² Patrizia Natale,² Letizia Gargano,²
Jonathan C Craig,⁶ David W Johnson,⁷ Marcello Tonelli,⁸ John Knight,⁹
Anna Bednarek-Skublewski,^{2,10} Eduardo Celia,² Domingo del Castillo,²
Jan Dulawa,^{2,11} Tevfik Ecder,² Elisabeth Fabricius,² João Miguel Frazão,^{2,12}
Ruben Gelfman,² Susanne Hildegaard Hoischen,² Staffan Schön,² Paul Stroumza²



DIAVERUM

Publications

Interventions for treating sexual dysfunction in patients with chronic kidney disease

ARTICLE IN PRESS

Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-analysis of Observational Studies

Sergio D'Amato¹, PhD; Maura Ida Mazzoni², MD; Paola Cenni², Article

David W. Johnson, MD, PhD³; Luisa Sagnelli⁴, MD; Fabio Pellegrini, MD^{5,6}; Giuseppe Lucherini, MD⁷; Jonathan Manzella Quarcio, MD, PhD⁸; Guido Gentile, MD^{9,10}; Marilena Quarcio, MD¹¹; Paul Gagliano, MD¹²; Marialuisa Quarcio, MD¹³; Juan Min Ferran, MD¹⁴; Anne Berthaut, MD¹⁵; Ruben Gutiérrez, MD¹⁶; David Conlon, MD¹⁷; Jorge Chavas Maldonado, MD¹⁸; Emanuele A. Leonardi¹⁹; and James Gokal, FRCR, FRCR²⁰, for the Diaverum International Working Group

Sexual Dysfunction in Women with ESRD Requiring Hemodialysis

Copyright © 2018 Diaverum. All rights reserved.

Background: Sexual dysfunction is an under-recognized problem in kidney disease (CKD). The prevalence, correlates, and predictors of this have not been evaluated comprehensively.

Study: A systematic review and meta-analysis.

Setting & Population: Records related using various platforms on electronic databases, conference proceedings, and patients with CKD for treatment periods from January 1, 1980, to December 31, 2016.

Subsidiary Criteria for Studies: Observational studies conducted involving a control group without CKD.

Outcome: "Sexual" study population.

Design: Cross-sectional studies involving men and women with CKD under dialysis treatment or not. Values from individual studies were reported by study investigators.

Results: A total of 1422 women (n = 1590) undergoing hemodialysis were recruited to a multicenter cross-sectional study conducted in this multinational network in Europe, North America, and Asia. The mean age was 54 years (SD, 11 years), and the mean eGFR was 14.73 mL/min (SD, 10.12 mL/min). About 10% of study subjects had CKD in stage 1–3, and 90% had CKD in stage 4–5. Women with eGFR ≤ 15 mL/min were less likely to report sexual dysfunction than those with a greater eGFR. In women, the reported prevalence associated with CKD ranged from 7% (studies using self-reporting questionnaires) to 40% (studies using structured interview). Women with CKD had a mean prevalence of sexual dysfunction of 20% (95% CI, 15.87 to 24.62); women without CKD had a mean prevalence of 10% (95% CI, 8.01 to 11.99).

Treatment Options for Sexual Dysfunction in Patients with Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials

Maria Chiara Vecchio,¹ Sankar D. Narayanan,^{2,3} David W. Johnson,⁴ Giuseppe Gentile,⁵ Gian Grattan,⁶ Massimiliano Quarcio,⁷ Valeria Sagnelli⁸, Marilena Quarcio,⁹ Carmine Bonifati,¹⁰ Emanuele A. Leonardi,¹¹ and Giovanni P.M. Strippoli,^{12,13*}

*Author for *Correspondence*. doi:10.31233/osf.io/3q7t1

Original Article

Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study

Cohort study and cluster randomization (CDR) in Hemodialysis Working Group

Copyright © 2018 Diaverum. All rights reserved.

Background: Erectile dysfunction (ED) is a common problem in men on hemodialysis (HD). The prevalence, correlates, and predictors of ED in men on HD have not been evaluated comprehensively.

Setting & Population: The CDR in Hemodialysis Working Group included 10 HD centers in 8 countries.

Subsidiary Criteria for Studies: Observational studies conducted involving a control group without CKD.

Outcome: "Sexual" study population.

Design: Cross-sectional studies involving men on HD and men without HD.

Results: A total of 1422 women (n = 1590) undergoing hemodialysis were recruited to a multicenter cross-sectional study conducted in this multinational network in Europe, North America, and Asia. The mean age was 54 years (SD, 11 years), and the mean eGFR was 14.73 mL/min (SD, 10.12 mL/min). About 10% of study subjects had CKD in stage 1–3, and 90% had CKD in stage 4–5. Women with eGFR ≤ 15 mL/min were less likely to report sexual dysfunction than those with a greater eGFR. In women, the reported prevalence associated with CKD ranged from 7% (studies using self-reporting questionnaires) to 40% (studies using structured interview). Women with CKD had a mean prevalence of sexual dysfunction of 20% (95% CI, 15.87 to 24.62); women without CKD had a mean prevalence of 10% (95% CI, 8.01 to 11.99).

Conclusion: Erectile dysfunction, defined as the inability to achieve or maintain an erection sufficient for sexual intercourse, is a common problem in men on HD. The prevalence of ED in men on HD is approximately 30% to 40%. Men with CKD have a higher prevalence of ED compared with men without CKD.

Methods: We conducted a multinational observational study involving 10 hemodialysis centers in 8 countries across Europe, North America, and Asia. Erectile dysfunction and sexual response were evaluated using the erectile function section of the International Index of Erectile Function questionnaire and the International Society of Urology classification of erectile dysfunction [1]. Erectile dysfunction may profoundly affect the quality of life in men with chronic kidney disease and is associated with depression, anxiety, and sexual dissatisfaction [2–4].

Results: Nine hundred and one patients (64%) had a stable sex life, and 259 (18%) had a sex life with a partner. Eighty-three per cent reported erectile dysfunction and 47% reported severe erectile dysfunction. These percentages were similar in all centers. The mean age was 54 years (SD, 11 years), and the mean eGFR was 14.73 mL/min (SD, 10.12 mL/min). About 10% of study subjects had CKD in stage 1–3, and 90% had CKD in stage 4–5. Women with eGFR ≤ 15 mL/min were less likely to report sexual dysfunction than those with a greater eGFR. In women, the reported prevalence associated with CKD ranged from 7% (studies using self-reporting questionnaires) to 40% (studies using structured interview). Women with CKD had a mean prevalence of sexual dysfunction of 20% (95% CI, 15.87 to 24.62); women without CKD had a mean prevalence of 10% (95% CI, 8.01 to 11.99).

Conclusion: Erectile dysfunction is a common problem in men on HD. The prevalence of ED in men on HD is approximately 30% to 40%. Men with CKD have a higher prevalence of ED compared with men without CKD.

Copyright © Diaverum

DIAVERUM

Conclusion

- Mesurer pour s'améliorer et être plus efficient (le meilleur soin au moindre coût)
- Le risque: soigner des chiffres et oublier de regarder le patient alors qu'il doit être au centre de notre système.



DIAVERUM



*Merci pour votre
attention*



DIAVERUM